1 Costopoulos C, Niespialowska-Steuden M, Kukreja

N, et al. Novel oral anticoagulants in acute coronary

syndrome[J]. Int J Cardiol, 2013, 167:2449-2455.

2 Shahpouri MM, Mousavi S, Khorvash F, et al.

Anticoagulant therapy for ischemic stroke:A review of

literature[J]. J Res Med Sci, 2012, 17:396-401.

3 Yates S, Sarode R. Novel thrombin and factor

Xa i n h ibitor s:cha l lenge s to r eve r s a l of thei r

anticoagulation effects[J]. Curr Opin Hematol, 2013,

20:552-557.

4 Kirchhof P, Breithardt G, Aliot E, et al. Personalized

management of atrial fibrillation:Proceedings from

the fourth Atrial Fibrillation competence NETwork/

European Heart Rhythm Association consensus

conference[J]. Europace, 2013, 15:1540-1556.

5 Pinto N, Dolan ME. Clinically relevant genetic

variations in drug metabolizing enzymes[J]. Curr

Drug Metab, 2011, 12:487-497.

6 Jonas DE, Mcleod HL. Genetic and clinical factors

relating to warfarin dosing[J]. Trends Pharmacol Sci,

2009, 30:375-386.

7 Lal S, Jada SR, Xiang X, et al. Pharmacogenetics

of target genes across the warfarin pharmacological

pathway[J]. Clin Pharmacokinet, 2006, 45:1189-1200.

8 Gaikwad T, Ghosh K, Kulkarni B, et al. Influence

of CYP2C9 and VKORC1 gene polymorphisms

on warfarin dosage, over anticoagulation and other

adverse outcomes in Indian population[J]. Eur J

Pharmacol, 2013, 710:80-84.

9 许强, 尹彤. 基因多态性对华法林低强度抗凝治疗稳

定剂量影响的前瞻性研究[J]. 中国循证心血管医学杂

志, 2013, 5:127-129.

10 You JH, Chan FW, Wong RS, et al. Is INR between

2.0 and 3.0 the optimal level for Chinese patients

on wa r f a r i n t he r apy for mode r a t e -i nt e n s it y

anticoagulation?[J]. Br J Clin Pharmacol, 2005,

59:582-587.

11 Yang J, Chen Y, Li X, et al. Influence of CYP2C9

and VKORC1 genotypes on the risk of hemorrhagic

compl icat ions in wa r fa r in-t reat ed pat ient s:A

systematic review and meta-analysis[J]. Int J Cardiol,

2013, 168:4234-4243.

12 Caldwell MD, Awad T, Johnson J A, et al. CYP4F2

genetic variant alters required warfarin dose[J]. Blood, 2008, 111:4106-4112.

13 Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic

variant (rs2108622) signif icantly contributes to

warfarin dosing variability in the Italian population[J].

Pharmacogenomics, 2009, 10:261-266.

14 罗志方, 江美兰, 章祖雄. 基因多态性对华法林抗凝治

疗维持剂量的影响[J]. 江西医药, 2013:48:312-315.

15 Roth J, Boudreau D, Fujii M, et al. PS3-4:Genetic risk

factors for major bleeding in warfarin patients in a

community setting[J]. Clin Med Res, 2013, 11:148.

16 于冰筠, 胡丽莉. 华南地区汉族人群MDR1基因单核

苷酸多态性研究[J]. 中山大学学报(自然科学版), 2011,

50:93-98.

17 De Oliveira AV, De Souza FA, Ribeiro DD, et al.

Association of the C3435T polymorphism of the

MDR1 gene and therapeutic doses of warfarin in

thrombophilic patients[J]. J Thromb Haemost, 2011,

9:2120-2122.

18 Saraeva RB, Paskaleva ID, Doncheva E, et al.

Pharmacogenetics of acenocoumarol:CYP2C9,

CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1

gene polymorphisms and dose requirements[J]. J Clin

Pharm Ther, 2007, 32:641-649.

19 Matagrin B, Hodroge A, Montagut-Romans A, et

al. New insights into the catalytic mechanism of

vitamin K epoxide reductase (VKORC1)-The catalytic

proper ties of the major mutations of rVKORC1

explain the biological cost associated to mutations[J].

FEBS Open Bio, 2013, 3:144-150.

20 Rieder MJ, Reiner AP, Gage BF, et al. Effect of

VKORC1 haplotypes on transcriptional regulation and

warfarin dose[J]. N Engl J Med, 2005, 352:2285-2293.

21 Veenstra DL, You JH, Rieder MJ, et al. Association of

Vitamin K epoxide reductase complex 1 (VKORC1)

variants with warfarin dose in a Hong Kong Chinese

patient population[J]. Pharmacogenet Genomics, 2005,

15:687-691.

22 Shalia KK, Doshi SM, Parikh S, et al. Prevalence of

VKORC1 and CYP2C9 gene polymorphisms in Indian

population and its effect on warfarin response[J]. J

Assoc Physicians India, 2012, 60:34-38.

23 Shuen AY, Wong BY, Fu L, et al. Evaluation of

the warfarin-resistance polymorphism, VKORC1

Asp36Tyr, and its effect on dosage algorithms in a

genetically heterogeneous anticoagulant clinic[J]. Clin

Biochem, 2012, 45:397-401.

24 Cavallari LH, Perera M, Wadelius M, et al. Association

of the GGCX (CAA)16/17 repeat polymorphism

with higher warfarin dose requirements in African Americans[J]. Pharmacogenet Genomics, 2012,

22:152-158.

25 Suriapranata IM, Tjong WY, Wang T, et al. Genetic

factors associated with patient-specific warfarin dose in

ethnic Indonesians[J]. BMC Med Genet, 2011, 12:80.

26 Cavallari LH, Butler C, Langaee TY, et al. Association

of apolipoprotein E genotype with duration of time to

achieve a stable warfarin dose in African-American

patients[J]. Pharmacotherapy, 2011, 31:785-792.

27 Wadelius M, Chen L Y, Eriksson N, et al. Association

of warfarin dose with genes involved in its action and

metabolism[J]. Hum Genet, 2007, 121:23-34.

28 Yoon IK, Choi YJ, Chang BC, et al. Effects of

inf lammatory cytokine gene polymorphisms on

warfarin maintenance doses in Korean patients with

mechanical cardiac valves[J]. Arch Pharm Res, 2013,

[Epub ahead of print].

29 Issac MS, El-Nahid MS, Wissa MY. Is there a role

for MDR1, EPHX1 and protein Z gene variants in

modulation of warfarin dosage? a study on a cohort

of the Egyptian population[J]. Mol Diagn Ther, 2014,

18:73-83.

30 Ma z z a c c a r a C, Co n t i V, Li g u o r i R, e t a l .

Warfarin anticoagulant therapy:a Southern Italy

pharmacogenetics-based dosing model[J]. PLoS One,

2013, 8:e71505.

31 黄盛文, 向道康, 吴海丽, 等. 五种基因多态性对华法

林用量个体差异影响的研究[J]. 中华医学遗传学杂志,

2011, 28:661-665.

32 Ozer M, Demirci Y, Hizel C, et al. Impact of genetic

factors (CYP2C9, VKORC1 and CYP4F2) on warfarin

dose requirement in the Turkish population[J]. Basic

Clin Pharmacol Toxicol, 2013, 112:209-214.

33 Paré G, Eriksson N, Lehr T, et al. Genetic determinants

of dabigatran plasma levels and their relation to

bleeding[J]. Circulation, 2013, 127:1404-1412.

34 Ross S, Pare G. Pharmacogenetics of antiplatelets and

anticoagulants:a report on clopidogrel, warfarin and

dabigatran[J]. Pharmacogenomics, 2013, 14:1565-

1572.

35 Pfeilschifter W, Luger S, Brunkhorst R, et al. The gap

between trial data and clinical practice--an analysis

of case reports on bleeding complications occurring

under dabigatran and rivaroxaban anticoagulation[J].

Cerebrovasc Dis, 2013, 36:115-119.

36 Scott SA, Patel M, Martis S, et al. Copy number

va r i a t ion a nd wa r f a r i n dosi ng:eva lu a t ion of

CYP2C9, VKORC1, CYP4F2, GGCX and CALU[J].

Pharmacogenomics, 2012, 13:297-307.